ESMO Gastrointestinal Cancers Congress 2026
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to ESMO Gastrointestinal Cancers Congress 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
ESMO Gastrointestinal Cancers Congress 2026
Event type: Oncology Congress, Medical Conference, Scientific Symposium, Clinical Research, Healthcare Innovation, Pharmaceutical and Medical Device Networking
Estimated attendance: Typically several thousand oncology professionals, including clinicians, researchers, hospital decision-makers, pharma teams, and academic specialists. Final footfall for 2026 should be validated against the organizer’s latest event release.
Overall buyer value: Very strong for healthcare, oncology, pharma, diagnostics, medtech, clinical research, and scientific education audiences. This is a high-quality B2B event where the attendee profile is much more valuable than a generic medical expo because it concentrates specialists directly involved in treatment decisions, research, procurement influence, education, and trial strategy.
1️⃣ Who attends: Buyers / Attendees
This event attracts a highly specialized healthcare audience centered on gastrointestinal oncology. The people attending are usually not casual visitors; they are deeply involved in diagnosis, treatment, research, drug development, scientific publishing, and hospital-based decision-making.
Main attendee groups:
- Medical oncologists, gastrointestinal oncologists, surgical oncologists, radiation oncologists
- Hospital cancer center leaders and oncology department heads
- Clinical researchers, principal investigators, trial coordinators, translational scientists
- Pharma and biotech medical affairs teams
- Commercial teams from oncology drug companies and diagnostics firms
- Pathologists, molecular diagnostics experts, lab medicine specialists
- Academic faculty, professors, fellows, residents, and medical students
- Healthcare procurement influencers tied to oncology treatment pathways
- Medical device and imaging companies focused on cancer care
- Professional societies, non-profits, and patient advocacy organizations
Buyer interpretation: If your client wants attendee or buyer data, the most valuable contacts are not just clinicians. The strongest B2B target layer is the combination of pharma, biotech, diagnostics, hospital leadership, cancer-center management, research institutions, and commercial oncology vendors. Those are the groups most likely to purchase, sponsor, adopt, or influence future medical solutions.
2️⃣ Where the show is happening + attendee geographic origin
Venue/location: The 2026 location should be confirmed from the official organizer announcement. The ESMO GI event is typically hosted in a major European congress destination with strong international connectivity, conference infrastructure, and healthcare access.
Attendee geographic origin: The audience is usually international and highly global in nature, with strong representation from:
- Europe
- North America
- Middle East
- Asia-Pacific
- Latin America
Geographic targeting insight: This is not a local audience. It is a global clinical and scientific audience with particularly strong concentration from countries with advanced oncology networks, major teaching hospitals, pharmaceutical R&D hubs, and high research output. Attendee origin often includes multinational teams traveling for scientific exchange, presentation, networking, and partnership discussions.
3️⃣ Audience reach
Reach type: Global
This event has a true international footprint. Even when held in Europe, the attendee base typically includes decision-makers and influencers from multiple continents. It is especially valuable for companies looking to reach:
- Oncology specialists with treatment influence
- Hospital and academic leaders
- Scientific and clinical research stakeholders
- Biopharma teams seeking KOL engagement
- Diagnostics and biomarker companies
This is one of those events where “global reach” is not just a marketing phrase; it reflects the real audience structure. The event is highly suitable for international attendee-list campaigns, congress sponsorship follow-up, KOL outreach, and clinical collaboration targeting.
4️⃣ Sample buyer company names + websites
Below is a buyer-focused sample table with companies that are strong fit accounts for this congress. These are the types of organizations most likely to attend, exhibit, sponsor, collaborate, or send decision-makers.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Roche | roche.com | Global Medical Affairs Lead, Oncology | Major oncology franchise, strong fit for scientific exchange, biomarker strategy, and congress engagement. |
| 2 | Novartis | novartis.com | Oncology Marketing Director / Medical Science Liaison Lead | Very strong GI oncology interest and high-value presence at global medical congresses. |
| 3 | Merck | merck.com | Director, Oncology Strategy / Clinical Development Lead | Strong fit for oncology clinical and commercial teams seeking specialist engagement. |
| 4 | Bristol Myers Squibb | bms.com | Medical Affairs Director, Oncology | Likely to engage in specialist oncology congresses, KOL networking, and research discussions. |
| 5 | Pfizer | pfizer.com | Global Product Manager, Oncology | Relevant for cancer drug awareness, physician education, and clinical stakeholder outreach. |
| 6 | Amgen | amgen.com | Oncology Medical Affairs Manager | Strong scientific and commercial oncology presence; good fit for congress lead generation. |
| 7 | AstraZeneca | astrazeneca.com | Director, Oncology Medical Strategy | Highly relevant for GI cancer research, treatment pathways, and physician engagement. |
| 8 | GSK | gsk.com | Medical Affairs Lead, Oncology | Good fit for pharma networking, clinical insight, and scientific exchange in oncology. |
| 9 | Guardant Health | guardanthealth.com | Director, Clinical Partnerships | Excellent fit for liquid biopsy, molecular diagnostics, and oncology precision medicine. |
| 10 | Illumina | illumina.com | Oncology Business Development Manager | Strong match for genomic testing, sequencing platforms, and biomarker-driven care. |
| 11 | Exact Sciences | exactsciences.com | Clinical Affairs Manager, Oncology Diagnostics | GI cancer screening and diagnostics relevance makes this a high-fit account. |
| 12 | MSD | msd.com | Regional Oncology Medical Director | Strong global oncology presence, ideal for scientific and clinical engagement. |
| 13 | Thermo Fisher Scientific | thermofisher.com | Precision Medicine Account Manager | Good fit for lab diagnostics, biomarker workflows, and research tools supporting cancer care. |
| 14 | IQVIA | iqvia.com | Clinical Research Director | Strong fit for trial intelligence, real-world evidence, and oncology research services. |
| 15 | Siemens Healthineers | siemens-healthineers.com | Oncology Solutions Director | Relevant for imaging, diagnostics, and hospital oncology infrastructure discussions. |
| 16 | Agilent Technologies | agilent.com | Biomarker Solutions Manager | Good fit for pathology, lab diagnostics, and translational cancer research. |
| 17 | BioNTech | biontech.com | Clinical Development Director, Oncology | Research-driven oncology company with strong scientific congress relevance. |
| 18 | Foundation Medicine | foundationmedicine.com | Medical Affairs Director, Precision Oncology | Excellent fit for genomic profiling, personalized medicine, and oncology specialist engagement. |
| 19 | Hologic | hologic.com | Strategic Accounts Manager, Diagnostics | Useful for diagnostic and pathology-related cancer workflow solutions. |
| 20 | Takeda | takeda.com | Oncology Portfolio Manager | Relevant for GI-related treatment categories and cross-functional oncology outreach. |
Best starter shortlist for client outreach: Roche, Novartis, AstraZeneca, Guardant Health, Illumina, Exact Sciences, Siemens Healthineers, IQVIA. These names usually give the strongest mix of budget, influence, scientific value, and potential attendee-list interest.
5️⃣ Job profiles, industries & event type
Best job profiles to target:
- Vice President, Oncology
- Global Medical Affairs Director
- Medical Science Liaison
- Clinical Development Director
- Head of GI Oncology
- Oncology Portfolio Manager
- Scientific Director
- Clinical Research Manager
- Director of Translational Research
- Precision Medicine Lead
- Hospital Cancer Center Director
- Professor of Oncology
- Pathology Lab Director
- Diagnostic Strategy Manager
- Market Access Manager, Oncology
- HEOR Manager
- Clinical Operations Lead
- Global Brand Manager, Oncology
- R&D Director
- Scientific Communications Manager
Industries to use from your industry list:
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Hospital & Health Care
- Research
- Higher Education
- Health, Wellness & Fitness
- Information Services
- Market Research
- Medical Practice
- Professional Training & Coaching
- Biotechnology and healthcare-adjacent diagnostics companies
Event type fit: This is best treated as a high-value specialist medical congress rather than a broad expo. The audience is smaller than a mass-market trade show, but the buying power and influence are much higher. A single attendee can represent a clinic, hospital system, trial network, research institution, or global pharma team.
6️⃣ Estimated attendance / expected footfall
Estimated attendance: Likely in the low-thousands to mid-thousands range, depending on final venue, program scale, and speaker lineup. Specialist oncology congresses usually have a concentrated but premium audience.
What footfall means here: Unlike consumer or general business shows, the true value is not just headcount. It is the concentration of high-quality attendees with specialist influence. Even a smaller congress can outperform a much larger event if the audience includes the right decision-makers.
Audience quality ranking: Very high. The event is especially strong for:
- KOL engagement
- Scientific lead generation
- Clinical partnership development
- Diagnostics and biomarker outreach
- Pharma and biotech relationship-building
7️⃣ Key focus areas & buyer engagement
Main focus areas:
- GI cancer treatment pathways
- Clinical trial updates and late-breaking research
- Precision oncology and biomarker strategy
- Immunotherapy and targeted therapy developments
- Pathology and molecular diagnostics
- Surgical innovation and multidisciplinary care
- Real-world evidence and outcomes research
- Academic collaboration and publication exchange
- New drugs, devices, and diagnostic platforms
Buyer engagement angle: The best engagement strategy is to speak the language of scientific value. Buyers and attendees at this event respond best to:
- Evidence-based positioning
- Clinical utility
- Research collaboration
- Patient outcome improvement
- Biomarker and precision medicine relevance
- Global oncology network access
If your client is selling attendee lists, the best angle is to identify the layers of influence: scientific leaders, medical affairs teams, research heads, diagnostics teams, and commercial oncology decision-makers. This is much more valuable than simply listing generic “conference attendees.”
8️⃣ Client product review requirement
Important: Please share your client’s website before finalizing the buyer list. The best targets depend heavily on what the client sells.
Example of how the buyer list changes by product type:
- If the client sells oncology software, target hospital oncology directors, medical affairs teams, and clinical research leaders.
- If the client sells diagnostics, target pathology labs, biomarker companies, molecular testing teams, and precision medicine leaders.
- If the client sells pharma services, target medical affairs, clinical development, market access, and real-world evidence teams.
- If the client sells medtech or imaging products, target hospital procurement influencers, oncology department heads, and imaging leads.
- If the client sells research tools or lab solutions, target translational research teams, academic labs, and clinical trial groups.
My recommendation: Send the client website first, then the buyer list can be narrowed to the most relevant companies, titles, and industry filters. That makes the list much more sellable and much easier for your internal team to prospect.
9️⃣ Industry suggestions based on your industry list
For this congress, the strongest industry filters are:
- Biotechnology
- Pharmaceuticals
- Medical Devices
- Hospital & Health Care
- Research
- Medical Practice
- Higher Education
- Health, Wellness & Fitness
- Information Services
- Market Research
- Professional Training & Coaching
Secondary industries to consider: Biotechnology-adjacent diagnostics, laboratory services, clinical research organizations, healthcare consulting, and scientific publishing-related companies. Even if those do not always appear as a perfect industry label, they are highly relevant company types for this event.
Final recommendation
This is a very strong global specialist congress for buyer-list sales, but it should be positioned correctly. Do not treat it like a broad tradeshow. It is a premium oncology congress with a focused audience of clinicians, researchers, pharma teams, diagnostics firms, and academic leaders.
Best buyer segments:
- Pharmaceutical and biotech oncology teams
- Diagnostics and molecular testing companies
- Hospital and cancer center leadership
- Academic oncology departments
- Clinical research and trial operations teams
- Scientific affairs and medical communications groups
Quality rating for B2B attendee-list sales: 9/10
Reason: High-quality specialist audience, global reach, strong commercial and scientific relevance, and excellent fit for premium healthcare and life-sciences buyers.
Data sheet
| Event Name | ESMO Gastrointestinal Cancers Congress 2026 |
| Event Date | 1 July 2026 – 4 July 2026 |
| Event Status | Upcoming |
| Venue | Munich |
| City | Munich |
| State / Region | Munich |
| Country | Germany |
| Organizer | European Society for Medical Oncology (ESMO) |
| Official Event Website | esmo.org |
| Event Type | Oncology congress, medical conference, scientific symposium, clinical research and healthcare innovation event |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology |
| Audience Reach | Global specialist medical audience with strong European concentration |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for current-year volume data; attendee-type profile is high-confidence based on the congress format and official ESMO positioning. |
| Main Purpose of Event | To present and discuss advances in gastrointestinal cancer treatment, translational research, diagnostics, clinical trials, multidisciplinary care, and oncology practice, while enabling scientific exchange and industry engagement across pharma, biotech, diagnostics, medtech, and hospital stakeholders. |
ESMO Gastrointestinal Cancers Congress is a specialist oncology meeting focused on cancers of the gastrointestinal tract, including colorectal, gastric, pancreatic, hepatobiliary, and related tumor types. As an ESMO-branded scientific congress, it typically attracts a high-value professional audience made up of medical oncologists, surgical specialists, radiation oncology leaders, translational researchers, academic investigators, hospital-based decision makers, and life sciences teams involved in treatment development and commercialization.
From a B2B lead-generation perspective, this is not a broad consumer-facing expo. It is a concentrated expert environment where treatment decisions, clinical-trial strategy, scientific collaboration, diagnostics adoption, and vendor evaluation are more relevant than general brand visibility. The event is especially valuable for healthcare, pharma, biotech, diagnostics, medtech, clinical research, and scientific education suppliers seeking access to specialist decision influencers and high-intent medical stakeholders.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Medical oncologists and GI cancer specialists | University hospitals, cancer centers, specialist clinics | Strong clinical influence over therapy selection, diagnostics usage, referrals, and trial participation | High value for pharma, diagnostics, medtech, and clinical education providers |
| Hospital cancer center leaders and department heads | Comprehensive cancer centers, academic medical systems, regional hospitals | Influence capital equipment, platforms, pathway adoption, and institutional partnerships | Important for enterprise sales, pilot programs, and strategic collaborations |
| Clinical researchers and principal investigators | Academic institutions, research hospitals, oncology networks | Drive trial design, site selection, biomarker research, and publication influence | Very relevant for CROs, lab services, eClinical, imaging, and translational research suppliers |
| Pharmaceutical medical and commercial teams | Pharma companies, oncology business units, regional affiliates | Evaluate scientific positioning, partnerships, KOL engagement, and market development | High relevance for medical affairs support, congress services, analytics, and partnership outreach |
| Biotech and translational innovation teams | Biotech firms, precision medicine ventures, biomarker developers | Assess clinical pathways, translational opportunities, and collaboration partners | Relevant for research tools, CDx partnerships, trial recruitment, and data offerings |
| Diagnostics and pathology decision influencers | Molecular pathology labs, hospital diagnostics units, precision oncology programs | Influence assay adoption, testing workflows, biomarker panel usage, and lab partnerships | High-value targets for molecular diagnostics, pathology tech, and workflow vendors |
| Medical device and interventional care specialists | Surgical oncology units, endoscopy teams, intervention centers | Influence device selection, procedural adoption, and supporting technologies | Relevant for device makers, imaging, procedural tools, and perioperative platforms |
| Hospital procurement and operations stakeholders | Hospital systems, public and private healthcare providers | Formal buying authority for equipment, service contracts, and institutional subscriptions | Most relevant for enterprise vendors with procurement-led sales cycles |
| CROs and clinical operations teams | Contract research organizations, site networks, trial management groups | Buy or influence outsourcing, data capture, site support, and patient recruitment services | Strong fit for clinical-tech, regulatory, data, and recruitment suppliers |
| Scientific publishers, associations, and education leaders | Medical societies, journals, CME platforms, academic groups | Influence dissemination, awareness, educational partnerships, and content sponsorship | Useful for thought-leadership, audience development, and specialist education campaigns |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Munich | Local hospital systems, university medicine, regional oncology specialists, local affiliate teams | Medium | Host-city attendance typically includes local clinical and academic participation. |
| Bavaria and Southern Germany | Regional cancer centers, university hospitals, diagnostics labs, pharma affiliates | Medium to High | Strong practical travel radius for German medical delegates and commercial teams. |
| Germany national market | University hospitals, cancer institutes, pharma and medtech country organizations | High | Germany is a major oncology, diagnostics, and clinical research market. |
| Western and Central Europe | Oncology societies, EU hospital systems, research investigators, affiliate medical affairs teams | Very High | ESMO meetings are typically strong draws for European specialists. |
| North America | Academic investigators, global pharma teams, biotech partnership leads | Medium | Participation is likely strongest among scientific and global corporate teams. |
| Asia-Pacific and Middle East | International researchers, oncology KOLs, multinational life sciences organizations | Medium | International reach is likely, but current-year geography split is not publicly confirmed. |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | ESMO-branded oncology congresses are internationally recognized and attract scientific, clinical, and life sciences participants beyond the host country. |
| European | Secondary concentration | The strongest practical concentration is likely across Europe due to the society base, travel accessibility, and clinical network relevance. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Current-year participant list not publicly released | Organizer-controlled attendee data | As of the research date, a public current-year attendee, buyer, speaker-organization, or exhibitor list suitable for verified company-level targeting was not publicly confirmed in the reviewed official sources. | esmo.org | Medical Oncologist; Head of Oncology; Clinical Research Director; Medical Affairs Director; Procurement Manager | Confirmed organizer source gap |
| Recommended next verification path | Official program and partner pages | For a higher-confidence company list, monitor official faculty, abstract, sponsor, and industry partner pages as they are published by ESMO. | esmo.org/meeting-calendar | Congress Sponsorship Lead; Medical Affairs Lead; Principal Investigator; Department Head | Confirmed official workflow recommendation |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Head of Oncology / Department Chair | Clinical Leadership | Director / Executive | High influence on treatment pathways, vendor evaluations, and strategic collaborations. |
| 2 | Medical Oncologist / GI Oncologist | Clinical Care | Manager / Director / Individual Contributor | Core clinical users and treatment decision influencers. |
| 3 | Clinical Research Director | Research / Trials | Director | Important for trial partnerships, site activation, and research technology purchasing. |
| 4 | Principal Investigator | Academic Research | Senior Individual Contributor / Director | Key scientific influencer for study collaboration and technology validation. |
| 5 | Medical Affairs Director | Medical Affairs | Director / VP | Critical for pharma and biotech scientific engagement and congress strategy. |
| 6 | Translational Science Lead | R&D / Translational Research | Director / Senior Manager | Relevant for biomarker, tissue analytics, and data-driven oncology solutions. |
| 7 | Pathology Director / Molecular Diagnostics Lead | Diagnostics / Laboratory | Director | Strong influence over assay adoption and precision-oncology workflows. |
| 8 | Procurement Manager | Procurement | Manager | Formal buyer for institutional contracts, equipment, and services. |
| 9 | Clinical Operations Director | Clinical Operations | Director | Relevant for CRO, trial platform, patient recruitment, and workflow solutions. |
| 10 | Business Development Director | Partnerships / Corporate Strategy | Director / VP | Important for biotech, medtech, platform partnerships, and licensing conversations. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core provider organizations and cancer centers attend or are represented. | Clinical adoption, procurement, diagnostics, workflow, and service sales. |
| 2 | Pharmaceuticals | A major audience segment for oncology congresses. | Medical affairs, scientific exchange, congress strategy, and partnership outreach. |
| 3 | Biotechnology | Precision oncology and emerging therapeutic developers are relevant participants. | Clinical collaboration, translational partnerships, and biomarker strategy. |
| 4 | Medical Devices | Relevant for oncology diagnostics, surgical, interventional, and monitoring technologies. | Device procurement, pilot programs, and specialist workflow integration. |
| 5 | Research | Academic and translational research is central to the congress. | Trial support, lab technology, analytics, and collaboration platforms. |
| 6 | Higher Education | University hospitals and academic medicine institutions are highly relevant. | Faculty outreach, research collaboration, and institutional programs. |
| 7 | Information Technology & Services | Supports oncology informatics, digital health, and scientific data workflows. | Clinical data systems, analytics, patient pathway tools, and interoperability. |
| 8 | Computer Software | Useful for oncology workflow, trial tech, registry, and knowledge management vendors. | Clinical workflow, ePRO, trial ops, and decision-support solutions. |
| 9 | Government Administration | Relevant where public hospital systems or national oncology programs are represented. | Public-sector health procurement and program collaboration. |
| 10 | Management Consulting | Healthcare strategy and life sciences consulting firms often engage around major scientific meetings. | Market access, scientific strategy, and partner-intelligence engagements. |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Unconfirmed | No public current-year attendance count found in reviewed official sources | Specialist medical congresses can be high quality even without large public footfall disclosures. |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Current-year exhibitor list not publicly verified in reviewed official sources | Industry partner pages may update closer to the event. |
| Buyer count | Not publicly confirmed | Unconfirmed | Organizer does not appear to publish a dedicated buyer count | More suitable to evaluate by audience quality than by buyer-volume metrics. |
| Speaker count | Not publicly confirmed | Unconfirmed | Depends on final scientific program publication | Scientific faculty data can later support company and institution mapping. |
| Sponsor count | Not publicly confirmed | Unconfirmed | Industry support information not fully public at research date | Monitor official partner pages for validation. |
| Historical attendance | No verified prior-year numeric figure included here | Not used | No current verified prior-year public count cited in this report | Avoided unsupported carry-forward estimates. |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Oncology treatment innovation | Evidence on new therapies, comparative outcomes, and pathway integration | Scientific exchange with clinicians and medical affairs teams | Pharma support services, medical communications, evidence platforms |
| Clinical research and trials | Site collaboration, recruitment efficiency, data capture, trial operations | Principal investigator and research-site outreach | CRO services, eClinical tools, patient recruitment, data platforms |
| Precision oncology and biomarkers | Improved testing, patient stratification, and molecular decision support | Engagement with pathology and translational leaders | Diagnostics, sequencing, pathology workflow, bioinformatics |
| Hospital oncology operations | Care coordination, pathway efficiency, multidisciplinary decision support | Department head and operations conversations | Workflow software, care coordination tools, service outsourcing |
| Medical devices and procedural support | Clinical utility, integration into treatment and diagnostic pathways | Specialist demos and clinical evidence discussions | Imaging, intervention, surgical, monitoring, or supportive devices |
| Scientific education and publishing | Dissemination of evidence and specialist education | Partnerships with societies, journals, and CME stakeholders | Content, education, communications, and knowledge-sharing solutions |
| Digital transformation in oncology | Data interoperability, analytics, registry, and outcome tracking | IT, research, and clinical leadership engagement | Clinical software, analytics, AI-enabled support, integration services |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Audience quality is strong because attendees are specialist oncology stakeholders rather than broad trade-show traffic. |
| Decision-maker availability | High | Clinical leaders, investigators, and life sciences directors are likely to be present or represented. |
| Data collection potential | Medium | High-value event, but public attendee data is usually limited at scientific medical congresses. |
| Apollo targeting potential | High | Strong for hospitals, pharma, biotech, diagnostics, CROs, and academic institutions. |
| Geographic targeting potential | High | Germany and wider Europe provide a clear regional targeting framework. |
| Best outreach approach | High | Use account-based outreach to cancer centers, oncology departments, medical affairs teams, and research leaders tied to GI oncology. |
| Overall lead quality | Very High | Excellent event for specialist B2B healthcare targeting despite limited public attendee disclosure. |
| Best use case | High | Best for targeted oncology outreach, KOL mapping, institutional account planning, and scientific partner development. |
| Limitations / risks | Medium | Public attendee lists may be unavailable; direct event list sales suitability is lower than open-directory trade fairs. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Medical Devices; Research; Higher Education; Information Technology & Services; Computer Software | Captures the most relevant provider, life sciences, and scientific account types. |
| Departments | Medical; Research; Clinical Operations; Procurement; Operations; Information Technology; Business Development; Partnerships | Aligns with clinical, scientific, operational, and buying stakeholders. |
| Seniority | Manager; Director; VP; CXO; Partner; Head | Focuses on decision makers and budget influencers. |
| Job titles | Head of Oncology; Medical Oncologist; GI Oncologist; Clinical Research Director; Principal Investigator; Medical Affairs Director; Pathology Director; Molecular Diagnostics Lead; Procurement Manager; Clinical Operations Director; Business Development Director | Targets the most relevant clinical, scientific, and commercial roles. |
| Geography | Germany first; then Switzerland, Austria, France, Italy, Spain, Netherlands, Belgium, United Kingdom, Denmark, Sweden, and other major European markets | Prioritizes the most practical and relevant ESMO attendance corridor. |
| Employee size | 51-200; 201-500; 501-1000; 1001-5000; 5001+ | Covers biotech scale-ups through large health systems and global pharma. |
| Keywords | oncology, gastrointestinal cancer, GI cancer, colorectal, pancreatic, gastric, hepatobiliary, precision oncology, biomarker, clinical trial, molecular diagnostics, cancer center | Improves role and account relevance for specialist oncology outreach. |
| Technologies | Use only if relevant to client: clinical trial software, pathology systems, sequencing tools, hospital analytics, CRM or engagement platforms | Narrow to tech-stack fit for digital health and software offerings. |
| Revenue range | Use selectively; mid-market to enterprise for hospitals and pharma, growth-stage filters for biotech | Improves segmentation by purchasing capacity. |
| Company type | Public, private, nonprofit, academic, government-affiliated provider organizations | Reflects the mixed ecosystem around oncology care and research. |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| European Society for Medical Oncology (ESMO) | Official organizer website | Organizer identity, congress brand, medical and scientific positioning | High |
| ESMO Meeting Calendar | Official event listing hub | Event-series validation, timing framework, and official meeting reference path | High |
| Organizer public materials reviewed as of 22 June 2026 | Verification note | No public current-year attendee count, exhibitor count, or open buyer directory was confirmed in the reviewed official sources at the time of research | High |
| User-supplied event details | Input brief | City, venue reference, and event dates used where not contradicted by reviewed official references | Medium |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to ESMO Gastrointestinal Cancers Congress 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.